Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Materials

Heparin Synthesis Improved

Chemoenzymatic method produces the anticoagulant in 40% yield

by Jyllian Kemsley
October 31, 2011 | A version of this story appeared in Volume 89, Issue 44

A new approach to preparing synthetic forms of the anticoagulant heparin provides pure heptasaccharides with improved yields over previous approaches (Science, DOI: 10.1126/science.1207478). Heparin is a variably sulfated glycosaminoglycan that is currently isolated from pig intestines and used clinically to prevent blood clotting. It is difficult to synthesize, yet synthetic forms are desired to help address quality-control and safety concerns. Past synthetic tactics suffered from low yields and, in enzymatic approaches, poor structural control. Now, a group led by Robert J. Linhardt of Rensselaer Polytechnic Institute and Jian Liu of the University of North Carolina, Chapel Hill, has developed optimized pathways to make two heparin heptasaccharide sequences. The synthetic schemes start with a disaccharide obtained from fermentation and use a combination of bacterial enzymes and chemical synthesis steps to produce the products with roughly 40% overall yields. The products show in vitro anticoagulant activity and pharmacokinetic properties similar to GlaxoSmithKline’s synthetic heparin pentasaccharide, fondaparinux sodium (Arixtra). The new chemoenzymatic methods should help pave the way to industrial-scale synthesis of additional products, the researchers say.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.